SGYPU Synergy Pharmaceuticals - Unit

Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President and CEO, Gary S. Jacob, Ph.D, will present at the ROTH 24th Annual Growth Stock Conference on Tuesday, March 13, 2012 at 5:00 p.m. PDT at the Ritz Carlton in Dana Point, CA.

To access live audio broadcast of this presentation, or the subsequent 90 day archive, log onto http://www.synergypharma.com/Investor_Relations_Information.html.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October 2011, Synergy initiated a Phase II/III 800-patient, 90-day repeated-oral-dose, placebo-controlled clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for 2012. Synergy's second GC-C agonist SP-333 is presently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.

CONTACT: Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924